PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus
Plus Therapeutics (NASDAQ:PSTV) closed at $0.5752 on Nov. 24, up nearly 8% on heavy volume after announcing a completed FDA Type B meeting for its REYOBIQ radiotherapeutic and a national coverage deal with Humana for its CNSide diagnostic. The stock remains volatile, trading between $0.16 and $2.31 over the past year.
